Chris Freeman

CCO Chris Freeman sells 24.4K GH shares at $118.67; holds 60.0K remaining after -28.9% reduction.

Chris Freeman, Chief Commercial Officer of Guardant Health, sold 24,406 shares for $2.9M on 2026-05-22 at $118.67 per share, reducing his non-derivative holdings by 28.9% to 60,034 shares; he retains 701 shares in option form. The sale occurs at a price 1.0% below the 52-week high of $121.01, with the stock up 34.8% over the prior 30 days and 25.8% over 90 days—a period of substantial appreciation. Notably, across his prior five trades in Guardant Health all executed on 2025-12-05, Freeman achieved a 100% well-timed rate at the 90-day horizon, with all subsequent holdings declining 8.7% to 13.2%, and his cross-ticker track record shows a 100.00% 90-day well-timed rate across 11 prior sells with an average 90-day return of -10.8%. The company remains unprofitable (net income of -$112.1M in the latest quarter) despite solid revenue growth of 32.9% year-over-year and a $15.9B market cap, creating a backdrop where an insider with a demonstrated pattern of selling before subsequent declines is now liquidating a material stake at elevated valuations.

Chief Commercial Officer Chris Freeman sold 31,452 shares for $3,241,621.17 across 11 transactions at blended average price $103.07

Chris Freeman, Chief Commercial Officer of Guardant Health, executed 11 separate sales totaling 31,452 shares for $3,241,621.17 on 2025-12-05, reducing his holdings by 54.8% from 57,439 to 25,987 shares. The company reported quarterly revenue of $265,196,000.00 and annual revenue growth of +31.0%, but posted a net loss of $-92,725,000.00 and was unprofitable over its most recent full fiscal year—a material divergence between top-line momentum and profitability. The sale's magnitude and the multi-tranche execution across a narrow price range ($101.40–$106.71) represent a substantial reduction in Freeman's equity stake, warranting examination of whether this aligns with disclosed equity plans or reflects updated portfolio positioning relative to the company's profitability trajectory.